DelveInsight's 'IGALMI Market Size, Forecast, and Market Insight Report' highlights the details around IGALMI, a sublingual film formulation ...

DelveInsight’s “Obsessive Compulsive Disorder Treatment Market Insights, Epidemiology and Market Forecast – 2034” report ...

Use of crinecerfont (Crenessity, Neurocrine Biosciences), a CRF-1 receptor antagonist recently approved by the FDA, in individuals with CAH can lead to a decrease in glucocorticoid requirements.

Neurocrine Biosciences, Inc. has shown significant growth since its 1996 IPO, with a current stock price around $100, reflecting an 850% increase. Ingrezza is the flagship, >$2bn p.a. selling ...

Fintel reports that on April 15, 2025, Needham upgraded their outlook for Neurocrine Biosciences (NasdaqGS:NBIX) from Hold to Buy. Analyst Price Forecast Suggests 75.41% Upside As of April 2 ...

Survey of Neurocrine Biosciences’ Crenessity suggests strong uptake across all patient segments. Sales could reach ~$1B in 2030. Feel unsure about the market’s next move? Copy trade alerts ...

During the last three months, 16 analysts shared their evaluations of Neurocrine Biosciences NBIX, revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ...

Learn more about whether Neurocrine Biosciences, Inc. or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

SAN DIEGO, April 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2025 financial results conference call and webcast for ...

Neurocrine Biosciences, Inc. discovers ... The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; ...